Figure 3From: Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX®Colon Cancer Assay Histogram of PCR positive controls (RNaseP) run prior to and during the clinical validation study. An RNaseP TaqMan assay, with gDNA as the template, was distributed across twelve wells of a 384-well qPCR plate and used as the qPCR positive control. A pre-specified acceptance criterion of 1%CV was applied. During the clinical validation study, only twenty eight samples (2%) failed this 1% CV specification, demonstrating a highly controlled process.Back to article page